CXCR4 blockade attenuates hyperoxia-induced lung injury in neonatal rats

Shelley Drummond, Shalini Ramachandran, Eneida Torres, Jian Huang, Dorothy Hehre, Cleide Suguihara, Karen Young

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Lung inflammation is a key factor in the pathogenesis of bronchopulmonary dysplasia (BPD). Stromal-derived factor-1 (SDF-1) and its receptor chemokine receptor 4 (CXCR4) modulate the inflammatory response. It is not known if antagonism of CXCR4 alleviates lung inflammation in neonatal hyperoxia-induced lung injury. Objective: We aimed to determine whether CXCR4 antagonism would attenuate lung injury in rodents with experimental BPD by decreasing pulmonary inflammation. Methods: Newborn rats exposed to normoxia (room air, RA) or hyperoxia (FiO2 = 0.9) from postnatal day 2 (P2) to P16 were randomized to receive the CXCR4 antagonist, AMD3100 or placebo (PL) from P5 to P15. Lung alveolarization, angiogenesis and inflammation were evaluated at P16. Results: Compared to the RA pups, hyperoxic PL pups had a decrease in alveolarization, reduced lung vascular density and increased lung inflammation. In contrast, AMD3100-treated hyperoxic pups had improved alveolarization and increased angiogenesis. This improvement in lung structure was accompanied by a decrease in the macrophage and neutrophil counts in the bronchoalveolar lavage fluid and reduced lung myeloperoxidase activity. Conclusion: CXCR4 antagonism decreases lung inflammation and improves alveolar and vascular structure in neonatal rats with experimental BPD. These findings suggest a novel therapeutic strategy to alleviate lung injury in preterm infants with BPD.

Original languageEnglish (US)
Pages (from-to)304-311
Number of pages8
JournalNeonatology
Volume107
Issue number4
DOIs
StatePublished - Jun 9 2015

Fingerprint

Hyperoxia
Lung Injury
Bronchopulmonary Dysplasia
Pneumonia
Lung
Blood Vessels
Air
Placebos
Chemokine Receptors
Bronchoalveolar Lavage Fluid
Premature Infants
Peroxidase
Rodentia
Neutrophils
Macrophages
Inflammation

Keywords

  • Angiogenesis
  • Bronchopulmonary dysplasia
  • CXCR4 blockade
  • Hyperoxia

ASJC Scopus subject areas

  • Developmental Biology
  • Pediatrics, Perinatology, and Child Health

Cite this

Drummond, S., Ramachandran, S., Torres, E., Huang, J., Hehre, D., Suguihara, C., & Young, K. (2015). CXCR4 blockade attenuates hyperoxia-induced lung injury in neonatal rats. Neonatology, 107(4), 304-311. https://doi.org/10.1159/000371835

CXCR4 blockade attenuates hyperoxia-induced lung injury in neonatal rats. / Drummond, Shelley; Ramachandran, Shalini; Torres, Eneida; Huang, Jian; Hehre, Dorothy; Suguihara, Cleide; Young, Karen.

In: Neonatology, Vol. 107, No. 4, 09.06.2015, p. 304-311.

Research output: Contribution to journalArticle

Drummond, S, Ramachandran, S, Torres, E, Huang, J, Hehre, D, Suguihara, C & Young, K 2015, 'CXCR4 blockade attenuates hyperoxia-induced lung injury in neonatal rats', Neonatology, vol. 107, no. 4, pp. 304-311. https://doi.org/10.1159/000371835
Drummond S, Ramachandran S, Torres E, Huang J, Hehre D, Suguihara C et al. CXCR4 blockade attenuates hyperoxia-induced lung injury in neonatal rats. Neonatology. 2015 Jun 9;107(4):304-311. https://doi.org/10.1159/000371835
Drummond, Shelley ; Ramachandran, Shalini ; Torres, Eneida ; Huang, Jian ; Hehre, Dorothy ; Suguihara, Cleide ; Young, Karen. / CXCR4 blockade attenuates hyperoxia-induced lung injury in neonatal rats. In: Neonatology. 2015 ; Vol. 107, No. 4. pp. 304-311.
@article{f47e476b638c41d0a2d54b2f9925afc0,
title = "CXCR4 blockade attenuates hyperoxia-induced lung injury in neonatal rats",
abstract = "Background: Lung inflammation is a key factor in the pathogenesis of bronchopulmonary dysplasia (BPD). Stromal-derived factor-1 (SDF-1) and its receptor chemokine receptor 4 (CXCR4) modulate the inflammatory response. It is not known if antagonism of CXCR4 alleviates lung inflammation in neonatal hyperoxia-induced lung injury. Objective: We aimed to determine whether CXCR4 antagonism would attenuate lung injury in rodents with experimental BPD by decreasing pulmonary inflammation. Methods: Newborn rats exposed to normoxia (room air, RA) or hyperoxia (FiO2 = 0.9) from postnatal day 2 (P2) to P16 were randomized to receive the CXCR4 antagonist, AMD3100 or placebo (PL) from P5 to P15. Lung alveolarization, angiogenesis and inflammation were evaluated at P16. Results: Compared to the RA pups, hyperoxic PL pups had a decrease in alveolarization, reduced lung vascular density and increased lung inflammation. In contrast, AMD3100-treated hyperoxic pups had improved alveolarization and increased angiogenesis. This improvement in lung structure was accompanied by a decrease in the macrophage and neutrophil counts in the bronchoalveolar lavage fluid and reduced lung myeloperoxidase activity. Conclusion: CXCR4 antagonism decreases lung inflammation and improves alveolar and vascular structure in neonatal rats with experimental BPD. These findings suggest a novel therapeutic strategy to alleviate lung injury in preterm infants with BPD.",
keywords = "Angiogenesis, Bronchopulmonary dysplasia, CXCR4 blockade, Hyperoxia",
author = "Shelley Drummond and Shalini Ramachandran and Eneida Torres and Jian Huang and Dorothy Hehre and Cleide Suguihara and Karen Young",
year = "2015",
month = "6",
day = "9",
doi = "10.1159/000371835",
language = "English (US)",
volume = "107",
pages = "304--311",
journal = "Neonatology",
issn = "1661-7800",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - CXCR4 blockade attenuates hyperoxia-induced lung injury in neonatal rats

AU - Drummond, Shelley

AU - Ramachandran, Shalini

AU - Torres, Eneida

AU - Huang, Jian

AU - Hehre, Dorothy

AU - Suguihara, Cleide

AU - Young, Karen

PY - 2015/6/9

Y1 - 2015/6/9

N2 - Background: Lung inflammation is a key factor in the pathogenesis of bronchopulmonary dysplasia (BPD). Stromal-derived factor-1 (SDF-1) and its receptor chemokine receptor 4 (CXCR4) modulate the inflammatory response. It is not known if antagonism of CXCR4 alleviates lung inflammation in neonatal hyperoxia-induced lung injury. Objective: We aimed to determine whether CXCR4 antagonism would attenuate lung injury in rodents with experimental BPD by decreasing pulmonary inflammation. Methods: Newborn rats exposed to normoxia (room air, RA) or hyperoxia (FiO2 = 0.9) from postnatal day 2 (P2) to P16 were randomized to receive the CXCR4 antagonist, AMD3100 or placebo (PL) from P5 to P15. Lung alveolarization, angiogenesis and inflammation were evaluated at P16. Results: Compared to the RA pups, hyperoxic PL pups had a decrease in alveolarization, reduced lung vascular density and increased lung inflammation. In contrast, AMD3100-treated hyperoxic pups had improved alveolarization and increased angiogenesis. This improvement in lung structure was accompanied by a decrease in the macrophage and neutrophil counts in the bronchoalveolar lavage fluid and reduced lung myeloperoxidase activity. Conclusion: CXCR4 antagonism decreases lung inflammation and improves alveolar and vascular structure in neonatal rats with experimental BPD. These findings suggest a novel therapeutic strategy to alleviate lung injury in preterm infants with BPD.

AB - Background: Lung inflammation is a key factor in the pathogenesis of bronchopulmonary dysplasia (BPD). Stromal-derived factor-1 (SDF-1) and its receptor chemokine receptor 4 (CXCR4) modulate the inflammatory response. It is not known if antagonism of CXCR4 alleviates lung inflammation in neonatal hyperoxia-induced lung injury. Objective: We aimed to determine whether CXCR4 antagonism would attenuate lung injury in rodents with experimental BPD by decreasing pulmonary inflammation. Methods: Newborn rats exposed to normoxia (room air, RA) or hyperoxia (FiO2 = 0.9) from postnatal day 2 (P2) to P16 were randomized to receive the CXCR4 antagonist, AMD3100 or placebo (PL) from P5 to P15. Lung alveolarization, angiogenesis and inflammation were evaluated at P16. Results: Compared to the RA pups, hyperoxic PL pups had a decrease in alveolarization, reduced lung vascular density and increased lung inflammation. In contrast, AMD3100-treated hyperoxic pups had improved alveolarization and increased angiogenesis. This improvement in lung structure was accompanied by a decrease in the macrophage and neutrophil counts in the bronchoalveolar lavage fluid and reduced lung myeloperoxidase activity. Conclusion: CXCR4 antagonism decreases lung inflammation and improves alveolar and vascular structure in neonatal rats with experimental BPD. These findings suggest a novel therapeutic strategy to alleviate lung injury in preterm infants with BPD.

KW - Angiogenesis

KW - Bronchopulmonary dysplasia

KW - CXCR4 blockade

KW - Hyperoxia

UR - http://www.scopus.com/inward/record.url?scp=84926176621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926176621&partnerID=8YFLogxK

U2 - 10.1159/000371835

DO - 10.1159/000371835

M3 - Article

C2 - 25825119

AN - SCOPUS:84926176621

VL - 107

SP - 304

EP - 311

JO - Neonatology

JF - Neonatology

SN - 1661-7800

IS - 4

ER -